Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25600556 | 1.00 | CNR1 (0.34) | CNR1CNR2HRH3NAMPTKDM4E | |
| SCHEMBL25605839 | 0.88 | EPHX1 (0.35) | HRH3NPC1ALDH1A1L3MBTL1TSHR | |
| SCHEMBL25600551 | 0.87 | KDM4E (0.43) | KDM4ECYP2C9CYP2C19NPC1ALDH1A1 | |
| SCHEMBL25600549 | 0.87 | KDM4E (0.43) | KDM4ECYP2C9CYP2C19NPC1ALDH1A1 | |
| SCHEMBL25631008 | 0.83 | HRH3 (0.40) | CNR1CNR2HRH3KDM4ECYP2C9 | |
| SCHEMBL25605834 | 0.83 | HRH3 (0.40) | CNR1CNR2HRH3KDM4ECYP2C9 | |
| SCHEMBL25029687 | 0.73 | NPC1 (0.40) | HRH3KDM4ECYP2C9CYP2C19NPC1 | |
| SCHEMBL24838147 | 0.73 | HRH3 (0.41) | CNR1CNR2HRH3KDM4ECYP2C9 | |
| SCHEMBL25605805 | 0.73 | EPHX1 (0.37) | HRH3ALDH1A1L3MBTL1TSHRKMT2A | |
| SCHEMBL25604717 | 0.72 | KDM4E (0.42) | HRH3KDM4ECYP2C19ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CNR1 4065/4885CNR2 4507/4885HRH3 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.